Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALIDOMIDE vs ADDERALL 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Multiple myeloma, relapsed or refractory (in combination with dexamethasone),Multiple myeloma, maintenance therapy post-autologous stem cell transplant,AIDS-related Kaposi sarcoma (off-label),Primary effusion lymphoma (off-label)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%.
Approximately 15–20% bound to plasma proteins, primarily albumin.
62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution.
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect.
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
Cr Cl 30-59 m L/min: 3 mg once daily. Cr Cl <30 m L/min: 2 mg once daily. Not recommended if Cr Cl <15 m L/min or requiring dialysis.
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
Safety and efficacy not established; no recommended dosing.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Pregnancy (absolute); women of childbearing potential not using effective contraception; men not using condoms during sexual activity with pregnant or non-pregnant women; hypersensitivity to pomalidomide or thalidomide analogs; prior severe dermatologic reactions to pomalidomide.
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
No data on M/P ratio; excreted in animal milk; potential for serious adverse reactions in infant; breastfeeding contraindicated during therapy and for at least 7 days after last dose.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
No specific dose adjustments in pregnancy due to contraindication; pharmacokinetic changes (e.g., increased clearance) theoretically require higher doses if used, but teratogenicity prohibits use; avoid exposure entirely.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (Cr Cl <45 m L/min).
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Do not become pregnant while taking this drug; use two reliable forms of contraception.,Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Take capsules whole, not crushed or chewed, with water.,Do not donate blood during treatment and for 4 weeks after stopping.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
"Dextropropoxyphene, an opioid analgesic, and pomalidomide, an immunomodulatory agent, both pose risks of QT interval prolongation. Co-administration may result in additive QT prolongation, increasing the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Additionally, dextropropoxyphene may exacerbate the sedative and respiratory depressant effects of pomalidomide, leading to excessive central nervous system depression."
"Concomitant use of pomalidomide and perampanel may result in additive central nervous system (CNS) depression due to their independent sedative properties. Pomalidomide, an immunomodulatory drug, is associated with somnolence and fatigue, while perampanel, an AMPA receptor antagonist, commonly causes dizziness, somnolence, and ataxia. This combination can lead to excessive sedation, impaired cognitive function, and increased risk of falls or accidents, particularly in elderly patients or those with impaired hepatic function."
"The concurrent use of desflurane, a halogenated inhalational anesthetic, with pomalidomide, an immunomodulatory agent, may potentiate the risk of severe hypotension and bradycardia due to additive cardiovascular depression. Desflurane directly depresses myocardial contractility and systemic vascular resistance, while pomalidomide can induce vasodilation and negative chronotropic effects. Clinically, patients may experience profound drops in blood pressure and heart rate, leading to reduced cardiac output and potential end-organ hypoperfusion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALIDOMIDE vs ADDERALL 12.5, answered by our medical review team.
POMALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.. ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALIDOMIDE and ADDERALL 12.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALIDOMIDE is: 4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.. The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALIDOMIDE and ADDERALL 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALIDOMIDE is classified as Category C. First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Ris. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.